2 Travel Stocks Gutted After Earnings

TripAdvisor and Expedia are both near the bottom of the Nasdaq today

Managing Editor
Nov 7, 2019 at 2:06 PM
facebook twitter linkedin

The U.S. stock market is continuing its torrid pace, soaring this time thanks to optimistic trade buzz. However, three stocks stocks sitting out the surge today are travel names Expedia Group Inc (NASDAQ:EXPE) and TripAdvisor Inc (NASDAQ:TRIP), as well as biotech concern ObsEva SA (NASDAQ:OBSV). Here's a quick look at what's moving the shares of EXPE, TRIP, and OBSV.

Options Traders Flood EXPE After Earnings Whiff

Expedia stock is down 26% at $100.18 at last check, after the travel company reported third-quarter earnings and revenue that fell short of expectations amid higher marketing costs and lower bookings numbers. Analysts have absolutely gutted the stock today, with no fewer than 13 brokerages issuing price-target cuts, the lowest coming from Mizuho to $115. Piper Jaffray -- who also downgraded EXPE to "neutral," expressed concern about search engine optimization. Expedia stock earlier tagged a new annual low of $99.78, and is pacing for its worst single-session drop since July 2013.

EXPE's options pits have exploded. With just under two hours left in trading today, 79,000 options have changed hands, 23 times the average intraday amount and volume already cruising past the previous annual high of 39,232. Leading the charge are the weekly 11/8 110-strike call and weekly 11/8 100-strike put.

TRIP Falls to Two-Year Lows Amid Google Threat

Not to be outdone, TripAdvisor stock is down 20% to trade at $32.34, and earlier fell to a two-year low of $29.27. Expedia's sector peer also reported a third-quarter earnings and revenue miss, with click-based sales lower amid greater competition from Google. Only RBC has come forward with a price-target cut though, to $32 from $50. TRIP's loss is pacing to be its worst since November 2017, and brings its year-to-date deficit to 40%. 

There's a similar frenzy going on among TRIP options traders. At last check, 33,000 options have been traded, 27 times the average intraday amount and volume toppling its previous annual high of 32,812 from February. The December 32.50 put is the most active, but there are also new positions being opened at the weekly 11/8 33-strike call.

ObsEva Cancels Fertility Drug, Stock Collapses

Near the bottom of the Nasdaq sits ObsEva stock, down 55.3% to trade at $3.56. The drugmaker scrapped its fertility drug nolasiban, after the oral drug failed trials. OBSV earlier traded as low as $3.34, and has now taken a 73.4% haircut in 2019. For a stock that's struggling so much, a shift in analyst sentiment could pressure it even lower. All eight of the brokerages in coverage rate OBSV a "buy" or better, and its $27 price target sits far above its June 2018 all-time high of $20.35.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners